Drew Ranieri
Stock Analyst at Morgan Stanley
(1.13)
# 3,484
Out of 4,711 analysts
163
Total ratings
40.45%
Success rate
-14.5%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $82.63 | +21.02% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $364.60 | +22.05% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $13.25 | +43.40% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $21.80 | +23.85% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.96 | +14.94% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $20.56 | +7.00% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $11.53 | -30.62% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $9.35 | +71.12% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $5 → $5.5 | $1.21 | +354.55% | 10 | Dec 4, 2023 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $3 → $3.5 | $3.05 | +14.75% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $18.70 | +103.21% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $75.44 | +27.25% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $16.08 | +61.69% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $227.68 | +29.57% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $178.16 | +57.16% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $10.67 | -53.14% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $29.50 | +137.29% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $524.43 | -42.80% | 6 | Apr 25, 2022 |
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $82.63
Upside: +21.02%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $364.60
Upside: +22.05%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $13.25
Upside: +43.40%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $21.80
Upside: +23.85%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.96
Upside: +14.94%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $20.56
Upside: +7.00%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $11.53
Upside: -30.62%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $9.35
Upside: +71.12%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $5 → $5.5
Current: $1.21
Upside: +354.55%
Organogenesis Holdings
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $3 → $3.5
Current: $3.05
Upside: +14.75%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $18.70
Upside: +103.21%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $75.44
Upside: +27.25%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $16.08
Upside: +61.69%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $227.68
Upside: +29.57%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $178.16
Upside: +57.16%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $10.67
Upside: -53.14%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $29.50
Upside: +137.29%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $524.43
Upside: -42.80%